AbCellera Biologics (ABCL) Goldman Sachs 45th Annual Global Healthcare Conference summary

Business overview and strategy

• Focuses on antibody therapeutics, evolving from a technology-driven platform to a clinical-stage biotech after 12 years of platform building.

• Transitioned from a partnership model to co-development and now to developing wholly owned clinical assets.

• Holds about $1 billion in liquidity, supporting the move into clinical development.

• Built a robust R&D engine integrating proprietary and state-of-the-art technologies, including automation and manufacturing infrastructure.

• Partnerships have validated the platform and created a portfolio of passive stakes in external programs.

COVID-19 impact and platform validation

• Rapidly developed the first COVID-19 monoclonal antibody in partnership with Eli Lilly, reaching the clinic in three months.

• Generated over $1 billion in revenue through royalties, enabling completion of the technology platform and funding internal pipeline development.

Internal pipeline and clinical programs

• ABCL575 (OX40L antagonist) targets atopic dermatitis and other autoimmune conditions, aiming for quarterly dosing and proof of concept in early clinical trials next year.

• ABCL635 is a first-in-class candidate for metabolic and endocrine disorders, with compelling primate data and expected early proof of concept by 2026.

• Pipeline expansion is supported by over $200 million in government funding to advance more than a dozen proprietary molecules.